12 March 2010
Dr Ludwin Monz is now the new CEO of Carl Zeiss Meditec, having taken over from Dr Michael Kaschke. Kaschke has been elected back to the Supervisory Board and was appointed its Chairman in a subsequent Supervisory Board meeting.
 |
11 March 2010
Last year a human trial involving administering gene therapy to Leber's congenital amaurosis (LCA) patients produced improvements in 12 children and young adults. The same researchers then conducted an animal study that found that a second injection into the previously untreated eye, was safe and effective with no signs of interference from immune reactions from the earlier injection. |
10 March 2010
New research is emerging from the Vanderbilt Eye Institute that indicates the first sign of injury in glaucoma occurs in the brain. |
10 March 2010
The Congress of the French Ophthalmology Society, SFO, will take place at the Palais des Congres, 2 place de la Porte Maillot, Paris, France, 8-11 May 2010.
|
03 March 2010
A worldwide licensing deal has been made between NicOx, the French biotech business and Bausch & Lomb for the former's candidate glaucoma drug NCX 116.
|
28 February 2010
San Francisco?Anti-vascular endothelial growth factor (VEGF) treatments for neovascular age-related macular degeneration represent the most significant advancement in ophthalmology over the past decade, according to 52% of respondents to an online survey of members of the American Academy of Ophthalmology conducted in December.
|
27 February 2010
Palomid 529 (P529) is to enter its Phase I trial in patients with AMD. A Phase I Open-Label Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of Single Intravitreal and Subconjunctival Doses of Palomid 529 in Patients with Advanced Neovascular Age-Related Macular Degeneration will according to Paloma Pharmaceuticals, be a dose-ranging study for safety but will also have an objective measure for efficacy.
|
26 February 2010
Eye advance online publication 12 February 2010; doi: 10.1038/eye.2010.9
|
25 February 2010
Eye advance online publication 12 February 2010; doi: 10.1038/eye.2010.3
|
| 
